Why agilon health Stock Is Back in Focus After Q2 Earnings

agilon health (AGL) drew fresh attention after reporting second quarter 2026 results on 5 August, with revenue of US$1,494.74 million and net income of US$17.96 million, alongside higher full year revenue and EBITDA guidance.

The company also reported net income of US$66.87 million for the first half of 2026 and issued third quarter revenue guidance of US$1,445 million to US$1,475 million. That updated outlook is now central to how investors are reassessing agilon health stock.

The Q2 earnings beat and raised guidance came after a volatile run for agilon health, with the share price up 9% on the day, delivering a very large year to date share price return and a 1 year total shareholder return of 249.19%, yet still showing a decline over 3 and 5 years.

If agilon health’s move has you rethinking your exposure to healthcare technology, this can be a good moment to survey other opportunities using our screener for 42 healthcare AI stocks

The Q2 jump in agilon health stock sits between two readings. Some investors see confirmation that the business reset is taking hold, while others see sentiment snapping back after steep multi year losses. How does the current valuation reflect that?

Most Popular Narrative: 24% Overvalued

agilon health closed at $96.90, while the most followed narrative anchors fair value at $78.14. That gap is driving a very different conversation compared to the Q2 earnings bounce.

Fair Value has risen from $60.36 to $78.14, which is an increase of about 29% in the analyst estimate for agilon health.

Future P/E has shifted from 29.70x to about 36.27x, which reflects a higher valuation multiple applied to the company’s projected earnings.

Want to see why this narrative supports a richer future multiple for agilon health than the wider healthcare sector? The key drivers are the revenue path, margin rebuild, and the profit run rate analysts are considering by the end of the decade.

Result: Fair Value of $78.14 (OVERVALUED)

However, the agilon health narrative still hinges on tighter medical cost control and smoother payer negotiations, both of which could disappoint and challenge the richer valuation story.

Another View on agilon health’s Valuation

The first narrative frames agilon health stock as 24% overvalued against a fair value of $78.14. Yet on simpler measures, agilon health screens as cheap. The stock trades on a P/S ratio of 0.3x versus peers at 2.2x and a fair ratio of 0.5x, which points to a sizeable valuation gap investors cannot ignore.

That low P/S relative to peers, the wider US Healthcare industry at 1.5x, and the 0.5x fair ratio suggests the market is pricing in a lot of execution risk rather than strong upside. The question is whether you see that gap as a margin of safety or a warning sign about future returns. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With agilon health attracting mixed reactions, it helps to look past headlines and into the underlying data to form your own view quickly. To weigh both the concerns and the potential rewards in one place, start with the 3 key rewards and 1 important warning sign

Looking for more agilon health style investment ideas?

If agilon health has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to uncover fresh stock ideas that match your approach.

• Target potential mispricings by scanning companies that appear attractively valued through the 52 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with resilient payouts through the 10 dividend fortresses.
• Prioritise capital protection first by reviewing companies flagged in the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.